Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 13, 2025, details the results of a Special Meeting of Stockholders held by Catheter Precision, Inc. The meeting addressed five proposals regarding capital structure, equity incentives, and auditor ratification. As of the record date (November 18, 2024), the company had 8,004,633 shares of common stock outstanding.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance actions and voting results.
Material Changes and Voting Results
Stockholders representing approximately 52.3% of outstanding shares (4,184,744 shares) voted on and approved all five proposals:
- Proposal 1 (Warrant Issuance): Approved the issuance of up to 10,695,962 shares upon exercise of Series K Common Stock Purchase Warrants. Votes: 1,432,775 For vs. 833,825 Against.
- Proposal 2 (Authorized Shares): Approved an amendment to increase authorized common stock from 30 million to 60 million shares. Votes: 2,823,644 For vs. 1,358,738 Against.
- Proposal 3 (Equity Plan): Approved an additional 1.5 million shares for the 2023 Equity Incentive Plan. Votes: 1,842,338 For vs. 426,114 Against.
- Proposal 4 (Auditor Ratification): Ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ended December 31, 2025. Votes: 3,726,746 For vs. 434,554 Against.
- Proposal 5 (Adjournment): Approved the ability to adjourn or postpone the meeting to solicit further votes if necessary. Votes: 3,262,238 For vs. 888,066 Against.
Outlook, Risks, and Unusual Items
The filing notes that a legal opinion previously filed with a Form S-3 registration statement (No. 333-284217) contained an assumption regarding the approval of the authorized share increase. Following the successful vote, a revised legal opinion removing this assumption has been filed as Exhibit 5.1. No specific forward-looking guidance, risk factors, or unusual financial items were disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the Certificate of Incorporation amendment increasing authorized shares to 60 million.
- Review the definitive proxy statement (Schedule 14A) filed on November 25, 2024, for detailed terms of the Series K Warrants and the 2023 Equity Incentive Plan.
- Confirm the filing status of the revised legal opinion (Exhibit 5.1) with the Delaware Secretary of State.
- Monitor future filings for the actual exercise of Series K warrants and the resulting dilution impact.